Tags: Epigenetics
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
announcements
October 15, 2019
$3.2 Million in New Funding Focused on Biomarkers and Moving Toward New Therapies
These recent investments reflect the ADDF's commitment to advancing tools for early detection, with an emphasis on exploring the different pathologies associated with aging.
blog
October 24, 2017
Combination Therapy: The Right Approach for Alzheimer’s
Learn why combination therapy holds such promise for treating Alzheimer's disease, and why Amylyx's drug is the first such therapy we are funding.
announcements
October 24, 2017
Innovative Alzheimer’s Combination Therapy Trial Supported by New Joint Funding Initiative
We are jointly funding a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.
announcements
April 24, 2017
ADDF Invests $300,000 to Support Phase 2 Clinical Trial of Epigenetic Therapy
A new investment of $300,000 in Oryzon Genomics continues our support of its groundbreaking epigenetic drug ORY-2001.
blog
January 17, 2017
Closing in on a Cure: Oryzon Genomics and ORY-2001
Discover ORY-2001, a revolutionary epigenetic therapy for Alzheimer's disease being developed by Oryzon Genomics in Barcelona, Spain.
blog
January 10, 2017
Top Five Alzheimer’s Advances in 2016
In 2016, we made great progress toward finding drugs to prevent and treat Alzheimer’s, as our top five advances demonstrate.
blog
September 12, 2016
Advancing Epigenetics: A New Approach to Treating Alzheimer’s Disease
Dr. Howard Fillit discusses epigenetic treatments, one of the newest and most promising areas of our portfolio.
announcements
July 7, 2016
Five New Grants Fund Promising Treatments & Biomarkers
The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.
announcements
May 10, 2016
Ten New Grants Support Alzheimer’s Drug Discovery and Biomarker Development
The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.
blog
September 24, 2014
New Drug Targets Are Highlight of Alzheimer’s Conference
Presenters at our recent conference shared exciting progress on new Alzheimer's drug targets and biomarkers.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).